The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial

• Váldodahkkit: Jianwei Liao (Dahkki), Liyun Yang (Dahkki), Luping Zhou (Dahkki), Hongbin Zhao (Dahkki), Xiao Qi (Dahkki), Yimin Cui (Dahkki), Dongsheng Ouyang (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background: Hyzetimibe is a novel inhibitor of cholesterol that specifically targets the NPC1L1 gene. Significant inter-individual variability suggests the existence of an abundance of poor responders and non-responders. In addition, the current literature is inconsistent and controversial regarding...